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& The aim of our study was to evaluate the possibility of using multiplex analysis of the cytokine
profile as a marker for successful aging by comparing cytokine plasmatic levels of a group of
Sicilian nonagenarians with those of young controls. We analyzed a panel of 17 cytokines, compre-
hensive of haematopoietic factors T helper 1 (Th1), Th2, inflammation regulatory cytokines, and
chemokines. The assay was carried out using the Luminex system. Interleukin (IL)-6 levels
(p¼ 0.01) were increased in nonagenarians, whereas no modifications of other proinflammatory
cytokines and chemokines were observed. Interferon-gamma (IFN-c) and IL-2 levels are unmodi-
fied, suggesting a substantial maintenance of relevant T cell functions. In addition, a significant
increase of IL-12 serum levels in nonagenarians versus young controls that might be related to the
increase of natural killer (NK) cell functions characterizing aging processes was observed. The
analysis of Th2 cytokines show an increase of IL-13 and a reduction of IL-4 levels mirroring
the maintenance of some effector’s mechanisms of the immunoresponse in advanced ages. Our
results suggest that the multiplex analysis of cytokine levels might be useful in defining a successful
aging profile.
Keywords circulating cytokine levels, immunoassay, Luminex, serum profile, successful
aging
INTRODUCTION
Centenarians provide the best example of successful aging. They are
people who have escaped major age-related diseases and have reached
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the extreme limit of human life in good clinical condition.[1] For example,
laboratory parameters of centenarians indicate that they are characterized
by reduced levels of blood glucose, transaminases, cholesterol, and platelets
with respect to older subjects with an age range between 65 and 85 years.[2]
In most of the cases, histories of centenarians reveal them to be free of can-
cer, dementia, diabetes, and cardiovascular diseases, which is surely due to a
successful interaction between environmental and genetic factors.
Advancing age is correlated to an increase of inflammatory response,
which is believed to be a direct consequence of the continuous attrition
caused by antigenic load during the life-span—a condition that is com-
monly called by the authors ‘‘inflamm-aging,’’[3] also sustained by the
immune system remodeling, which physiologically occurs during aging
(‘‘immuno-senescence’’). It is a slow but inexorable process leading to an
immune system that shows peculiar features, predisposing older people
to a different kind of reaction to injuries in comparison to young
individuals.[4]
In particular, the dedicated immune system tissues, such as as thymus,
bone marrow, spleen, and lymph nodes, undergo involution or they show
regressive phenomena. The number of germinal centers is reduced, and
there is a progressive loss of cell-mediated immunity, generally recognizable
by a tendency toward the switch from Th1 vs. Th2 type response.[5] More-
over, in the aging process, and even in centenarians, there is a redistri-
bution of monocytes, neutrophils, B and T subsets, and a quite normal
number of T lymphocytes, even if these cells mostly show a memory pheno-
type, whereas a progressive reduction of virgin cells is observable, which
makes the old individuals unable to respond to antigens not previously
encountered.[6]
Several studies have largely demonstrated an important role of genetic
background in the achievement of advanced age. A group of genes that has
often been tested for association with successful aging is that which influ-
ences inflammation and immune responses. Among these, there are genes
coding for interleukins. Our group has demonstrated that particular cyto-
kine polymorphisms, especially located on the functional promoter
sequence of important cytokines genes such as interleukin (IL)-1, IL-6,
tumor necrosis factor-a (TNF-a), interferon-c (INF-c), and IL-10, may influ-
ence the susceptibility to age-associated diseases or may alternatively con-
tribute to the genetic background associated with longevity.[7–13] These
data highlight the role of cytokine production in determining the success-
ful or unsuccessful aging phenotype. In this view, it seems of some interest
to check the possibility of identifying a serum cytokine profile that might
characterize successful aging. To reach this result, a technology that allows
a contemporaneous and highly precise determination of a large number of
cytokines should be applied.
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In this article, we report data evaluation by Luminex technology of
the blood levels of 17 pro- and anti-inflammatory cytokines and chemo-
kynes, which are crucial in the orchestration of the immune response,
in order to identify the circulating cytokine profile of subjects >90 years
old.
MATERIALS AND METHODS
Subjects Recruitments
In our study, two groups of subjects were tested. In particular, we ana-
lyzed sera from 44 Sicilian ultra-nonagenarians (age >90 years) and 79 con-
trol subjects consisting of a group of healthy young Sicilian individuals,
aged between 30 and 50 years old. None of ultra-nonagenarian subjects
recruited for the study show any major age-related diseases or severe cogni-
tive impairment (dementia or neoplastic, cardiovascular, or infectious dis-
ease), nor did they receive any drugs that influence immune functions at
the time of the study. Their age was verified by archival records at the City
Hall and=or church registries, verifying the concordance between reported
age and personal chronologies (age of marriage and of military service for
men, age of first and last pregnancy for women, age of children, etc.). The
Sicilian ethnicity of all the participants at the study was established by
confirming that all four grandparents were born in Sicily, in order to gain
a certain guarantee of a homogeneous population, as immigration and
intermarriage have historically been rare at the beginning of the last cen-
tury.[14] Written informed consent for enrolling in the study and for
personal data management was obtained from all subjects according to
Italian laws.
Evaluation of Cytokine Blood Level Assay
Each subject underwent a fasting blood sampling. The blood samples
were collected in lithium heparin additioned vacutainer tubes, immediately
centrifuged at 1800 rpm for 15 min to isolate cell free plasmas that were
immediately stored at 80C.
Immediately before the cytokine assay, thawed samples were centri-
fuged at 12,000 rpm for 5–10 min to allow precipitation of any lipids excess
that may interfere with subsequent analysis.
The samples were tested for a panel of 17 cytokines and chemo-
kines [IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p70), IL-13,
IL-17, IFN-c, TNF-a, monocyte chemoattractant protein-1 (MCP-1),
macrophage inflammatory protein-1b (MIP-1b), granulocyte-macrophage
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colony-stimulating factor (GM-CSF), and granulocyte colony-stimulating
factor (G-CSF)] using Bio-plex kit (BioRad, Milan, Italy) and following
the manufacturer’s instructions. The assay was carried out using the
Luminex system (BioRad, Mu¨nchen, Germany), based on the measure-
ment of fluorescent signals released by a suspension of microspheres,
bringing immobilized multiplex cytokine specific antibodies in 96-well
plates. The combination of a fluorimetric signal of microspheres with that
released by a secondary antibody allows us to measure cytokine concen-
tration–related signals converted by a processor. Briefly, 50 mL of samples
diluted 1:4 in a dilution buffer were incubated at room temperature in
the presence of beads conjugated with specific antibodies for the different
cytokines. After a wash to remove the excess of not bound serum compo-
nents, an incubation with the biotin conjugated secondary antibodies was
performed. Finally, after another washing step and the streptavidin-PE com-
plex addition, the fluorimetric signal was detected by using the Luminex
plate reader. The assay was performed using an eight-point standard curve
for every cytokine. Samples were analyzed on a Luminex 100 device
(BioRad), and the data were evaluated using the Bio-Plex Manager software
(BioRad). Standards, internal controls, and samples were reported as
means of duplicate measurements.
Statistics
All the data are shown as mean concentrations (pg=ml) standard
error (SE). Differences in cytokine levels among nonagenarians and
healthy controls were assessed by the Mann–Whitney test. Differences were
considered significant when a p value <0.05 was obtained.
RESULTS AND DISCUSSION
As we already described in the Introduction, aging is characterized by a
remodeling process of immune system, where several functions are
reduced, whereas others remain unchanged or are increased.[15] A few
notable instances are, surely, a persistence of a low-grade chronic inflamma-
tory status and a consistent increase of activated cells that progressively fill
the immunological space,[4] considered as the compartment occupied
by the immune cell subsets and a reduced capability to cope with new
immunological stimulations. In this scenario the reshaping of cytokine
production network seems to play a central role.
In this article, we focus on the evaluation of the circulating cytokine
profile of a group of healthy nonagenarians in an attempt to describe a
plasmatic cytokine profile that might characterize successful ageing. To
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reach this goal the highly sensitive multiplex Luminex technology is
applied to minimize differences in cytokine evaluation due to differences
of performances among methodologies useful to measure a single cytokine
at a time.
The selected panel of cytokines measured included the following: (a)
hematopoietic cytokines; (b) proinflammatory and anti-inflammatory
cytokines and chemokines; (c) Th1, Th2, and Th17 cytokines.
As reported in Table 1, the levels of the three hematopoietic cytokines
analyzed (IL-7, G-CSF, and GM-CSF) are not significantly different among
young and nonagenarians groups. However, it seems relevant that IL-7,
implied in lymphopoiesis, is reduced in nonagenarians with a difference
with young subjects near the statistically significant threshold. As reported
by Pawelec et al.[6] dysregulated hematopoiesis is seen in older individuals,
raising the possibility that this could contribute to altered immune funct-
ion in aged persons. Actually, data from some experimental models
seems to suggest that a reduced production of IL-7 might be implied in
TABLE 1 Plasmatic Cytokine Concentration Expressed as Mean (pg=mL)
Standard Error
Cytokines Young Controls (79) Nonagenarians (44) P Value
IL-7 1.60 0.10 1.0 0.30 0.06
G-CSF 0.55 0.15 0.30 0.08 0.14
GM-CSF 5.11 1.06 11.50 4.41 0.16
IL-2 11.03 1.49 9.30 2.03 0.11
IL-12(p70) 2.88 0.6 7.20 1.53 0.01
IFN-g 10.22 3.93 8.24 2.69 0.27
IL-4 0.55 0.08 0.35 0.05 0.03
IL-5 0.65 0.09 0.66 0.06 0.76
IL-13 0.77 0.05 1.23 0.19 0.02
IL-1b 11.89 4.02 11.24 3.40 0.26
IL-6 5,16 3.61 11.18 2.53 0.01
TNF-a 5.80 1.99 7.72 1.61 0.81
IL-10 0.44 0.04 0.75 0.20 0.11
IL-17 7.36 1.34 17.10 3.32 0.09
IL-8 31.08 84.9 36.10 5.89 0.41
MCP-1 79.90 17.06 130.80 29.57 0.14
MIP-1b 125.70 10.71 139.90 7.54 0.47
Differences in cytokine levels among nonagenarians and healthy controls
were assessed by the Mann–Whitney test.
86 M. Palmeri et al.
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ita
 di
 Pa
ler
mo
], 
[M
ari
sa
 Pa
lm
eri
] a
t 0
3:2
9 0
9 J
an
ua
ry
 20
12
 
progressive reduction of the number of naive lymphocytes associated with
aging.[16]
One of the major characteristics of senescence is the constant pres-
ence of a low-grade inflammatory status characterizing aging. This subcli-
nical inflammation produces a persistent immune system activation,
resulting in continuous low-grade tissue damage, as well as in the
reduction of the normal immune system response to new antigens caused
by a net consuming of naive cells.[3,4,17] As reported in Table 1, nonagen-
arians show a significant increased level of IL-6 (p value¼ 0,01), which
seems to suggest that an increased IL-6 level might be detected also in
a successful aging phenotype to confirm the age-dependent pro-inflamma-
tory imbalance. Moreover, increased levels of IL-6 could also be related
to the increased level of IL-17 (Table 1), even if the result did not reach
statistical significance (p¼ 0.09), as IL-6 acts to enhance the Th17
lymphocytes’ activity by stimulating the production of IL-17, which is
involved in inflammation and in the amplification of the inflammatory
response. However, the concentrations of other proinflammatory and
anti-inflammatory cytokines and chemokines crucial in the balance of
inflammation (IL-1-beta, TNF-a, IL-8, MCP-1, MIP-1b, and IL-10), are
not significantly different between the two groups of subjects, and this
allows us to speculate that the cytokine profile of the studied nonagenar-
ians is characterized by a very low grade of proinflammatory cytokine sig-
nature. In addition, the slight increase of antinflammatory IL-10 observed
is in agreement with our previous description of the genetic background
owned by centenarians, as we previously found among these subjects a sig-
nificant increase of the frequency of carriers possessing the allele related
to higher IL-10 production.[10,12]
IFN-c and IL-2 levels are not modified in nonagenarians with respect to
the controls. As reported by different groups, Th1 and IL-2 cytokine pro-
duction is generally decreased in older subjects,[6] even if in selected
healthy old subjects (SENIEUR protocol) these cytokines seem to be nor-
mally secreted.[6] Our data obtained in healthy nonagenarians seem to sug-
gest that the preservation of IFN-c and IL-2 production might be one of the
components of the successful aging phenotype. In particular the mainte-
nance of an equilibrated concentration is favorable to prevent an excessive
or prolonged Th1 response. Concerning IL-2 secretion maintenance in the
oldest subjects, in our previous study, no modifications of genotypic and
allelic frequencies of the IL-2 functional polymorphism 330 T=G were
demonstrated.[18]
In our study we found a statistically significant increase in serum levels
of IL-12 in nonagenarians in comparison with controls (p value¼ 0.01)
(Table 1). Conflicting data on IL-12 production in old subjects have been
published.[6] Both increase and reduction in IL-12 secretion have been
Nonagenarians Cytokine Serum Levels 87
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ita
 di
 Pa
ler
mo
], 
[M
ari
sa
 Pa
lm
eri
] a
t 0
3:2
9 0
9 J
an
ua
ry
 20
12
 
reported in animal experimental models, as well as after in vitro stimulation
of human peripheral blood cells.[6] Our data, which were obtained by eval-
uating IL-12 serum levels, might be related to the increase of monocytes
and NK cells, which characterize aging processes, mirrored by a very
well-preserved cytotoxic activity. Indeed, a well-preserved NK cell activity
can be considered a factor of longevity.
It is reported that advanced-aged individuals are characterized by high
plasma levels of immunoglobulins.[19] In particular IgG, IgA, and IgE
levels are increased. Analysis of Th2 cytokines shows similar IL-5 levels
among nonagenarians and young controls. Instead the analysis of other
Th2 cytokines shows divergent results. Actually, a significant reduction
of IL-4 levels (p¼ 0.04) is accompanied by a significant increase of
IL-13 levels in nonagenarians versus controls (p¼ 0.02). In a recent arti-
cle, we focused on B cells in the aged by studying the expression of some
surface markers. In particular, in older people and in centenarians, there
was an increase of CD27þB cells with a decrease of CD27B lympho-
cytes. CD27 is considered a marker of primed memory B cells. The dec-
rement of virgin CD27B lymphocytes cells and the concurrent
increase of memory CD27þB lymphocytes seem to have an impact on
the antibody repertoire of older individuals.[19–21] In this view, our data
might be related to the different role played by IL-4 and IL-13 in the
Th2 switch and B cell response maintenance in aging. Actually the Th2
switch, where IL-4 has a major key role, is already strongly reduced in
advanced aged individuals, where there is a higher ratio between differen-
tiated memory cells and virgin naı¨ve ones, whereas, IL13 is mainly pro-
duced by primed Th2 cells.[22] So, the contemporaneous circulating
IL-4 reduction and IL-13 increase detected in nonagenarians might mir-
ror Th2 committed cells related to increasing age. Our results taken
together confirm that, although the cytokine profile is modified by aging,
we were able to show that long-living persons maintain unchanged levels
of some crucial cytokines useful in preserving crucial immune-system
function, and this might contribute to a person reaching such an
advanced age.
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